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ABSTRACT 
 
The POT1 protein forms part of the shelterin complex, which binds and protects 
telomeres. Germline mutations in the POT1 gene have recently been shown to be 
involved in tumors in different tissues such as familial colorectal, glioma and melanoma 
tumors, which demonstrate the importance of this gene. Recently, we uncovered a 
mutation in the POT1 gene (p.R117C) as causative of cardiac angiosarcomas in 
families with multiple tumors. Our in silico studies predicted that the POT1 p.R117C 
protein had lost the ability to interact with TPP1 and ssDNA. In vitro studies 
corroborated this prediction, and showed that this lack of function leads to abnormally 
long telomeres with increased fragility. 
In order to better understand the spectrum of mutations in the POT1 gene and 
its relation with tumorigenesis, we extended the study to families with multiple tumors 
(with and without angiosarcomas) and sporadic angiosarcomas and cardiac sarcomas. 
We found four new mutations that were not described previously and another 
patient carrying the previously described p.R117C mutation. In silico studies predicted 
that these new mutations were damaging in the same manner as previously described 
for the POT1 p.R117C mutation. These mutations were present in both, families and 
sporadic cases with angiosarcomas and sarcomas, although the major part was 
involved in families with AS and in cardiac tumors. The wide spectrum of mutations in 
the POT1 gene leading to different tumorigenesis processes demonstrates the general 




POT1 (protection of telomeres 1) is a component of the so-called shelterin 
complex, which binds and protects telomeres (Palm & de Lange 2008). POT1 binds 
TPP1 from the shelterin complex through a conserved domain located at the C-
terminus of POT1; in turn, TPP1 binds the TRF1/2 proteins (Figure 1a). Two other 
conserved domains of the POT1 protein (oligonucleotide/oligosaccharide-binding 1 and 
2; OB1 and OB2) are located at the N-terminus and directly interact with the telomere 
and the residues p.146 to p.152 of the POT1 protein compose the OB-fold. The 
stacking residues T1; T2; A3; G4; G5; G6; T7; T8; A9 and G10 interact with the single-
stranded (ss) telomeric DNA sequence TTAGGGTTAG (Lei et al. 2004) (Figure 1b). 
Mutations in the POT1 gene have recently been shown to be involved in tumors 
in different tissues. Germline mutations in the POT1 gene were described to be 
responsible for familial glioma (Bainbridge et al. 2014), melanoma (Robles-Espinoza et 
al. 2014; Shi et al. 2014) and colorectal cancer (Chubb et al. 2016). Somatic mutations 
in the POT1 gene were also described to be involved in chronic lymphocytic leukemia 
(Ramsay et al. 2013). Recently, we identified a deleterious missense germline mutation 
(rs780936436) in the POT1 gene (p.R117C) which caused cancer in three families with 
multiple tumors including cardiac angiosarcomas (CAS) and in one family with breast 
angiosarcomas (AS) (Calvete et al. 2015) (Figure 1b). A constitutional mutation in the 
POT1 gene (R432*) was also found in one out of five sporadic CAS tumors (Kunze et 
al. 2014) (Figure 1b). 
In silico studies suggested that the POT1 p.R117C protein had lost the ability to 
interact with ssDNA and TPP1 (Figure 1a) (Calvete et al. 2015). In vitro studies 
confirmed these in silico predictions and indicated that carriers of this mutation had 
reduced levels of POT1 bound to the telomere and to the TPP1 protein, which 
correlated with abnormally long telomeres with increased fragility (Calvete et al. 2015) 
(Figure 1a). Longer telomeres were also found in carriers of mutations in the POT1 
gene described in melanoma tumors (Robles-Espinoza et al. 2014; Shi et al. 2014). 
In order to better understand the role of POT1 not only as telomere protector, 
but also as one of the main genes responsible for the development of different familial 
cancer types, we extended our study to 34 families with multiple tumors (10 with and 
24 without angiosarcomas) and 30 cases of sporadic angiosarcomas and cardiac 
sarcomas. 
  
MATERIALS AND METHODS 
 
Patients 
A total of 64 patients with different tumors were selected for the whole POT1 
gene study. They were two CAS and 8 AS from 10 families with multiple tumors, 24 
families with multiple tumors but without angiosarcomas, 26 sporadic cases of CAS, 2 
cardiac sarcomas, and 2 sporadic angiosarcomas that were not cardiac 
(Supplementary Table 1). Patients were selected from Spain (Spanish National Cancer 
Research Center, Hospital Puerta de Hierro, Hospital de Sant Pau, Corporació 
Sanitària Parc Taulí and Institut Català d'Oncologia), Germany (Liebig-University) and 
France (Rouen University Hospital). The ethics committees of the various institutions 
approved this study, and written informed consent was obtained from all participants 
prior to inclusion in the study. 
 
DNA samples 
Genomic DNA was isolated from peripheral blood lymphocytes using the 
FlexiGene DNA Kit (QIAGEN). DNA from normal tissue was extracted from paraffin-
embedded tissue samples using the DNeasy® Blood & Tissue Kit (Qiagen, Cat. No. 
69504) following the manufacturer's instructions. 
 
POT1 gene study 
 Sanger sequencing of the entire POT1 gene was performed in the full series of 
selected patients. The primers used for Sanger sequencing of the 15 exons are listed 
in Supplementary Table 2. PCR was performed using standard conditions. 
 
In silico studies 
The heat map representation of predicted tolerance to independent amino acid 
substitutions was made using SNAP2 software (implemented in PredictProtein), which 
assesses the potential functional impact of the variants (Yachdav et al. 2014). Potential 
splice site alterations was calculated with Alamut®-Mutation Interpretation Software 
version 2.3.2 (available at www.interactive-biosoftware.com) and SplicePort (Dogan et 
al. 2007). Solvent accessibility of amino acids (PACC score) was predicted using the 
PROFAcc algorithm (Schlessinger & Rost 2005) implemented in ProteinPredict 
(Yachdav et al. 2014). Protein-binding regions were predicted using the ISIS algorithm 
(Ofran & Rost 2007).  
RESULTS 
 
Sequencing of the entire POT1 gene in the different series uncovered four new 
mutations (one nonsense and three missense mutations) that were not described 
before, and the same mutation described in Calvete et al. (Calvete et al. 2015) (Table 
1). The missense mutations were all within functional domains (Figure 1b) and they 
were considered damaging by the functional predictors and the tolerance to amino acid 
change score (Table 1). 
Regarding the families with multiple tumors including angiosarcomas, two 
mutations were found in the POT1 gene. However, no mutations in the POT1 gene 
were found in any individual of the 24 studied families with multiple tumors without 
angiosarcomas. A missense mutation (p.T497L) was found in a breast AS from a 
French family with multiple tumors (Table 1). Putative protein-protein binding sites were 
calculated for the putative protein containing the mutation. The protein-protein binding 
site at position p.499 was lost in this putative protein, as previously observed for the 
POT1 p.R117C protein. This resulted in the loss of capability of the mutant protein to 
interact with the TPP1 protein (Supplementary Table 3) (Figure 1b). This prediction 
was confirmed by in vitro assays (Calvete et al. 2015). A truncating mutation (Gln301*) 
was found in an individual with CAS from a second family (Table 1). The putative POT1 
Gln301* protein was not included in the in silico study because the entire TPP1 domain 
is deleted and it is therefore expected to have lost its ability to interact with TPP1. 
Regarding the sporadic tumors series, a mutation (p.P116L) was found in an  
individual with CAS (Table 1). The same protein-protein binding site at position p.499 
for TPP1 binding is lost in the putative POT1 p.P116L protein (Supplementary Table 3). 
In addition, the putative POT1 p.P116L protein changed the orientation from exposed 
(wt) to buried (PACC score for solvent accessibility) for two residues in the OB-fold 
(p.152 and p.266), as previously described for the POT1 p.R117C protein (Figure 1b) 
(Supplementary Table 4). Therefore, the POT1 p.P116L protein is also predicted to 
have lost its capacity to bind ssDNA. The sporadic tumor series also contained an 
individual with a cardiac sarcoma carrying the previously described p.R117C mutation 
and another one with an intronic variant (c.547-1) (Table 1). The intronic variant was 
located in the splice acceptor site of the 4th intron, and might lead to skipping the 
acceptor site for splicing out intron 4. The splice acceptor score was calculated for the 
wild type POT1 DNA (score: 0.61; acceptance threshold: 0.45) (Supplementary Figure 
1). POT1 c.547-1G>A putatively lost the acceptor site (score: 0.00; acceptance 
threshold: 0.45), which would result in the skipping of the splice acceptor site. 
Therefore, removal of 4th intron of POT1 c.547-1G>A putatively leads to removal of 
exon 5 as well (Supplementary Figure 1). The in silico studies with the putative POT1 
c.547-1G>A protein were performed assuming that the entire 5th exon was lost. In the 
putative protein containing the POT1 c.547-1G>A mutation, the site at p.499 for binding 
TPP1 was also predicted to be lost (Figure 1b) (Supplementary Table 3) (no RNA was 
available) 
In summary, two different mutations in the POT1 gene were found in families 
with multiple tumors including angiosarcomas but no POT1 mutations were found in 
families without angiosarcomas. In addition, another three mutations in the POT1 gene 
were found in three sporadic tumors, one in a sporadic CAS patient and two in 
sporadic cardiac sarcoma individuals. All putative proteins are expected to lose their 
ability to interact with TPP1, as previously demonstrated in vitro for the POT1 R117C 
protein (Calvete et al. 2015). Moreover, the putative POT1 p.P116L protein is predicted 
to have lost its capacity to form the OB-fold as well. No significant accessibility score 





Mutations in the POT1 gene 
Four new predicted damaging mutations (p.R116C p.Gln301*, p.T497L and 
c.547-1G>A) (Table 1) that appear to be involved in tumorigenesis have been added to 
the mutation spectrum of the POT1 gene. In silico studies predicted that these new 
mutations have the same effect on the POT1 protein as described for the POT1 
p.R117C mutation (Calvete et al. 2015) (Supplementary Tables 3 and 4). Therefore, 
these mutant proteins are expected to be unable to bind to TPP1. In addition, the 
mutation p.P116L is predicted to be defective in its interaction with ssDNA. In vitro 
studies of the POT1 p.R117C protein substantiated the in silico prediction (Calvete et 
al. 2015); therefore, the new mutations described in the current study are expected to 
deregulate POT1 function in the same manner and to increase telomere length, making 
them unstable. Carriers of the mutations described in this work are expected to have 
abnormally long telomeres with increased damage and fragility. Variants in telomere 
structure and maintenance genes lead to telomere fragility, which is commonly 
associated with different cancer types (Karami et al. 2016). 
 
POT1 and angiosarcomas 
In the present work, mutations in the POT1 gene were found in 20% of the 10 
studied families with multiple tumors including angiosarcomas (cardiac and breast), but 
no mutations were found in 24 families with multiple tumors without angiosarcomas. 
Mutations in the POT1 gene were also found in 3 out of the 30 sporadic tumors (2 in 
cardiac sarcomas and 1 in CAS) (Table 2a). The mutations in the sporadic cardiac 
sarcoma individuals demonstrate that the mutations in the POT1 gene described in this 
work are not limited to angiosarcomas.  
Because cardiac tumors are rare, we added previously published cases (Kunze 
et al, 2014; Calvete et al, 2015). Therefore, Table 2b includes 12 additional families 
with multiple tumors with angiosarcomas, four of them had the POT1 p.R117C 
mutation. Ten additional families with multiple tumors without angiosarcomas did not 
present POT1 mutations (Calvete et al. 2015). Regarding sporadic CAS patients, one 
out of five additional patients presented a truncating mutation (p.R432*) in the POT1 
gene (Kunze et al. 2014). Based on these data, we can conclude that mutations in the 
POT1 gene are present in 27.3% and 11.4% of families with multiple tumors including 
angiosarcomas and sporadic CAS tumors, respectively (Table 2b). 
 
 
POT1 mutations in other diseases 
Other described POT1 mutations involved in familial glioma and familial 
melanoma tumors also led to abnormally long telomeres (Robles-Espinoza et al. 2014; 
Shi et al. 2014; Bainbridge et al. 2014). No information regarding telomere length was 
available for the colorectal cancer patients carrying POT1 mutations (Chubb et al. 
2016). 
All these mutations described in different types of tumors appear randomly 
distributed along the gene and the conserved domains, independently of the cancer 
type (Figure 1b). Table 2c summarizes the frequency of alterations in these diseases. 
Although the incidence of POT1 mutations is lower than in AS cases, they should be 
considered especially in familial melanoma (2.4%). 
In summary, we observed that mutations in the POT1 gene are not limited to 
familial angiosarcomas, but also occur in sporadic angiosarcomas and cardiac 
sarcomas. POT1 mutations are described mainly in cardiac tissue pathologies and a 
putative relation between cardiac tumors and malfunction of telomere biology might 
exist. The wide spectrum of mutations in the POT1 gene leading to tumorigenesis in 
different tissues demonstrates the general importance of this gene. However, the 
molecular landscape that leads to tumorigenesis is still not well understood. 
 
 
FIGURE LEGENDS  
 
Figure 1: Shelterin and telomere regulation. a) Above: POT1, which belongs to the 
shelterin complex, binds telomeres to regulate telomerase activity. Below: Carriers of 
the POT1 p.R117C mutation show reduced levels of POT1 bound to telomeres and to 
TPP1, which correlates with abnormally long and fragile telomeres (Calvete et al. 
2015). b) POT1 binds TPP1 through the conserved domain located at the C-terminus. 
The POT1 R117C protein has lost the ability to bind to TPP1 due to the lost of the 
protein-binding site at position p.499 (white arrow). The OB1 and OB2 domains at the 
N-terminus directly interact with the telomere. The OB-fold (residues p.146 to p.152) is 
shown (white rectangle). The stacking residues T1; T2; A3; G4; G5; G6; T7; T8; A9; 
G10 (grey arrowheads) interact with the ssDNA. In the putative POT1 R117C protein, 
the PACC solvent accessibility scores of positions p.152 and p.266 (T8; A9) have 
changed from exposed (wt) to buried, which results in loss of its ability to bind to 
ssDNA. Mutations in the POT1 gene found in this work (blue arrowheads), in a 
previous sporadic CAS (Kunze et al. 2014) (green arrowhead), in melanoma tumors 
(Robles-Espinoza et al. 2014; Shi et al. 2014) (white arrowheads), in glioma tumors 
(Bainbridge et al. 2014) (black arrowhead) and in colorectal cancer (Chubb et al. 2016) 
(red arrowhead) are shown. 
 
Supplementary Figure 1: In silico analysis of splice site skipping in the POT1 c.547-
1G>A variant. Above: Splice acceptor site (black triangle) of the 4th intron of wild type 
(wt) POT1 DNA (score: 0.61; acceptance threshold: 0.45). Below: Skipping of the 
splice acceptor site (black triangle) of the 4th intron in POT1 c.547-1G>A DNA (score: 
0.00; acceptance threshold: 0.45) that would remove the 5th exon. 
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